Im­mu­sanT scores a $40M round for PhII celi­ac study, with biotech vet Tom Daniel join­ing the board

Cel­gene vet Tom Daniel’s role as a part­ner at Arch Ven­ture will take him to the board at Cam­bridge, MA-based Im­mu­sanT, a biotech start­up that has now raised a $40 mil­lion B round from Arch and Vat­era. The mon­ey is be­ing ear­marked to get the biotech’s lead ther­a­py through Phase II, with da­ta ex­pect­ed around the mid­dle of 2019.

The biotech is spe­cial­iz­ing in cre­at­ing im­mune sys­tem tol­er­ance to thwart au­toim­mune dis­eases. And it’s go­ing af­ter celi­ac dis­ease as its lead pro­gram in a first step to­ward us­ing the same tech for type 1 di­a­betes and oth­er ail­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER